Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real life experience of apremilast in psoriasis and arthritis psoriatic patients: Preliminary results on metabolic biomarkers
Sara Mazzilli, Caterina Lanna, Carlo Chiaramonte, et al.
The Journal of Dermatology (2020) Vol. 47, Iss. 6, pp. 578-582
Closed Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Intersecting Pathways: Nonalcoholic Fatty Liver Disease and Psoriasis Duet—A Comprehensive Review
Daniel O. Costache, Horia Blejan, Damian Cojocaru, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2660-2660
Open Access | Times Cited: 8
Pharmacogenomics: An Update on Biologics and Small-Molecule Drugs in the Treatment of Psoriasis
Valerio Caputo, Claudia Strafella, Terenzio Cosio, et al.
Genes (2021) Vol. 12, Iss. 9, pp. 1398-1398
Open Access | Times Cited: 40
Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies
Deepak Balak, Stefano Piaserico, Ismail Kasujee
Psoriasis Targets and Therapy (2021) Vol. Volume 11, pp. 151-168
Open Access | Times Cited: 30
Apremilast as a Potential Targeted Therapy for Metabolic Syndrome in Patients with Psoriasis: An Observational Analysis
Elena Campione, Nikkia Zarabian, Terenzio Cosio, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 8, pp. 989-989
Open Access | Times Cited: 4
Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease—results of the Immune Metabolic Associations in Psoriatic Arthritis study
Lyn D Ferguson, Susanne Cathcart, Dominic Rimmer, et al.
Lara D. Veeken (2021) Vol. 61, Iss. 3, pp. 1026-1034
Open Access | Times Cited: 27
Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey Into the Immunologic Crosstalk
Lucia Novelli, Ennio Lubrano, Vincenzo Venerito, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 26
Psoriatic arthritis: one year in review 2022
Cosimo Cigolini, Federico Fattorini, Stefano Gentileschi, et al.
Clinical and Experimental Rheumatology (2022)
Open Access | Times Cited: 18
The Role of Glutathione-S Transferase in Psoriasis and Associated Comorbidities and the Effect of Dimethyl Fumarate in This Pathway
Elena Campione, Sara Mazzilli, Monia Di Prete, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 17
The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast
I. Arias de la Rosa, Maria Dolores López‐Montilla, Cristóbal Román-Rodríguez, et al.
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 676-693
Open Access | Times Cited: 17
High Systemic Disease Risk and Therapeutic Delays in Plaque Psoriasis: A Retrospective Analysis of Apremilast Use in the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)
Kave Shams, Jennifer Montgomery, J. E. Morley, et al.
Dermatology and Therapy (2025)
Open Access
The efficacy of apremilast in pemphigus: a systematic review of case reports
Roudin Alhasawi, Esraa A. Shaheen, Noura Mohammed Alshabanat, et al.
Dermatology Reports (2025)
Open Access
Apremilast effectively inhibits TNFα‐induced vascular inflammation in human endothelial cells
Matthias S. Otto, Britta Dorn, T. Grasmik, et al.
Journal of the European Academy of Dermatology and Venereology (2021) Vol. 36, Iss. 2, pp. 237-246
Open Access | Times Cited: 23
Pharmaco-Omics in Psoriasis: Paving the Way towards Personalized Medicine
Charalabos Antonatos, Paschalia Asmenoudi, Mariza Panoutsopoulou, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7090-7090
Open Access | Times Cited: 8
Effects on Lipid Profile after One Year of Apremilast Therapy in Patients with Psoriasis: A Monocentric Experience
Prisca Guerra, Antonella Di Cesare, Elia Rosi, et al.
Life (2024) Vol. 14, Iss. 3, pp. 395-395
Open Access | Times Cited: 3
<p>An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis</p>
Maria Sole Chimenti, A. D’antonio, Paola Conigliaro, et al.
Biologics (2020) Vol. Volume 14, pp. 53-75
Open Access | Times Cited: 23
Apremilast as a target therapy for nail psoriasis: a real-life observational study proving its efficacy in restoring the nail unit
Caterina Lanna, Gaia Maria Cesaroni, Sara Mazzilli, et al.
Journal of Dermatological Treatment (2020) Vol. 33, Iss. 2, pp. 1097-1101
Closed Access | Times Cited: 22
Apremilast Improves Endothelial Glycocalyx Integrity, Vascular and Left Ventricular Myocardial Function in Psoriasis
Ignatios Ikonomidis, George Pavlidis, Nikolaos P.E. Kadoglou, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 2, pp. 172-172
Open Access | Times Cited: 13
Experimental Pharmacological Management of Psoriasis
Elena Campione, Terenzio Cosio, Monia Di Prete, et al.
Journal of Experimental Pharmacology (2021) Vol. Volume 13, pp. 725-737
Open Access | Times Cited: 18
Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases
Andrea Picchianti Diamanti, Francesca Romana Spinelli, Maria Manuela Rosado, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 5, pp. 2638-2638
Open Access | Times Cited: 17
The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
Murlidhar Rajagopalan, Sunil Dogra, Abir Saraswat, et al.
Psoriasis Targets and Therapy (2021) Vol. Volume 11, pp. 109-122
Open Access | Times Cited: 17
Anti- and non-tumor necrosis factor-α-targeted therapies effects on insulin resistance in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
Chrong‐Reen Wang, Hung‐Wen Tsai
World Journal of Diabetes (2021) Vol. 12, Iss. 3, pp. 238-260
Open Access | Times Cited: 16
Psoriasis comorbidities in Germany: A population-based study on spatiotemporal variations
Jobst Augustin, Sandra Wolf, Brigitte Stephan, et al.
PLoS ONE (2022) Vol. 17, Iss. 3, pp. e0265741-e0265741
Open Access | Times Cited: 12
Diabetes and obesity burden and improvements in cardiometabolic parameters in patients with psoriasis or psoriatic arthritis receiving apremilast in a real-world setting
Cristi Cavanaugh, Kate K. Orroth, Xi Qian, et al.
JAAD International (2024) Vol. 16, pp. 244-251
Open Access | Times Cited: 2
Metformin Inhibits HaCaT Cell Proliferation Under Hyperlipidemia Through Reducing Reactive Oxygen Species via FOXO3 Activation
Li Zhang, Xiaoling Liu, Min Huang, et al.
Clinical Cosmetic and Investigational Dermatology (2022) Vol. Volume 15, pp. 1403-1413
Open Access | Times Cited: 10
Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review
Kelly Torosian, Esha Lal, Arthur Kavanaugh, et al.
Seminars in Arthritis and Rheumatism (2023) Vol. 59, pp. 152165-152165
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top